Neurobiological Operating Cycle from 2010 to 2026
| NTII Stock | USD 0.0001 0.00 0.00% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 2.93 | Current Value 2.78 | Quarterly Volatility 834.0415854 |
Check Neurobiological Technologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurobiological Technologies' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 1.3 M or Research Development of 12.9 M, as well as many indicators such as Price To Sales Ratio of 0.75, Dividend Yield of 0.0 or PTB Ratio of 0.84. Neurobiological financial statements analysis is a perfect complement when working with Neurobiological Technologies Valuation or Volatility modules.
Neurobiological | Operating Cycle | Build AI portfolio with Neurobiological Stock |
Latest Neurobiological Technologies' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Neurobiological Technologies over the last few years. It is Neurobiological Technologies' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurobiological Technologies' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Neurobiological Operating Cycle Regression Statistics
| Arithmetic Mean | 204.87 | |
| Geometric Mean | 3.95 | |
| Coefficient Of Variation | 407.10 | |
| Mean Deviation | 380.77 | |
| Median | 2.55 | |
| Standard Deviation | 834.04 | |
| Sample Variance | 695,625 | |
| Range | 3.4K | |
| R-Value | (0.41) | |
| Mean Square Error | 618,372 | |
| R-Squared | 0.17 | |
| Significance | 0.10 | |
| Slope | (67.42) | |
| Total Sum of Squares | 11.1M |
Neurobiological Operating Cycle History
About Neurobiological Technologies Financial Statements
Investors use fundamental indicators, such as Neurobiological Technologies' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Neurobiological Technologies' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 2.93 | 2.78 |
Currently Active Assets on Macroaxis
When determining whether Neurobiological Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurobiological Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurobiological Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurobiological Technologies Stock:Check out the analysis of Neurobiological Technologies Correlation against competitors. For more detail on how to invest in Neurobiological Stock please use our How to Invest in Neurobiological Technologies guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurobiological Technologies. If investors know Neurobiological will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurobiological Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neurobiological Technologies is measured differently than its book value, which is the value of Neurobiological that is recorded on the company's balance sheet. Investors also form their own opinion of Neurobiological Technologies' value that differs from its market value or its book value, called intrinsic value, which is Neurobiological Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurobiological Technologies' market value can be influenced by many factors that don't directly affect Neurobiological Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurobiological Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurobiological Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurobiological Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.